Physician profile
Eddy Simon
NPI 1851385058
$7,351.20
in general payments reported to CMS, 2019-2025
39 companies · $712 in 2025
The $712 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $793 · 2021: $1,201 · 2022: $1,581 · 2023: $1,030 · 2024: $1,226 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,457.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $749.27 | 2020-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals Lp | $717.53 | 2019-2024 | Fasenra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $657.60 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $484.81 | 2019-2025 | Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $355.84 | 2019-2023 | Steglatro, Segluromet |
| Abbvie INC. | $330.55 | 2021-2025 | Linzess, Viberzi |
| Philips North America LLC | $277.51 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $197.65 | 2024-2025 | Lumryz |
| Bayer Healthcare Pharmaceuticals INC. | $194.69 | 2021-2022 | |
| Amgen INC. | $185.07 | 2021-2024 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $184.81 | 2022-2023 | Quviviq |
| Horizon Therapeutics Plc | $184.62 | 2019-2023 | Krystexxa |
| Cardiovascular Systems INC. | $160.01 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $151.02 | 2019-2025 | Uptravi |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddy Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.